News from ajmc.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top ajmc.com News

FDA · United StatesBy Jacqueline Howard, CNN (CNN) — The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday. The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, Bayer said. It works by blocking the brain chemicals responsible for hot flashes and night sweats –…See the Story
New Menopause Drug to Target Hot Flashes without Hormones Gets FDA Approval
89% Center coverage: 46 sources

Science · United StatesScientists have discovered how leukemia cells outsmart a leading treatment and may have found a way to stop them. Scientists from Rutgers Health and collaborating institutions have uncovered why a widely used leukemia drug stops working for many patients and have identified a possible method to reverse that resistance. The research team found that a [...]See the Story
Scientists Discover How Leukemia Cells “Cheat Death” and Evade Treatment
75% Center coverage: 4 sources

United States · United StatesOn Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The Blenrep approval is supported by data from the pivotal DREAMM-7 phase 3 trial. Multiple myeloma is the third most common blood cancer globally and is …See the Story
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - GSK (NYSE:GSK)
100% Center coverage: 1 sources